Gelteq (GELS) Competitors $1.05 -0.04 (-3.24%) As of 03/28/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsTrendsBuy This Stock GELS vs. ELYM, DTIL, BLUE, ATNM, FBLG, MDCX, NRXP, SRZN, IRD, and GBIOShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Eliem Therapeutics (ELYM), Precision BioSciences (DTIL), bluebird bio (BLUE), Actinium Pharmaceuticals (ATNM), FibroBiologics (FBLG), Medicus Pharma (MDCX), NRx Pharmaceuticals (NRXP), Surrozen (SRZN), Opus Genetics (IRD), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Eliem Therapeutics Precision BioSciences bluebird bio Actinium Pharmaceuticals FibroBiologics Medicus Pharma NRx Pharmaceuticals Surrozen Opus Genetics Generation Bio Gelteq (NASDAQ:GELS) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk. Is GELS or ELYM more profitable? Gelteq's return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Eliem Therapeutics N/A -47.03%-45.97% Which has higher earnings and valuation, GELS or ELYM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/AN/AN/AN/AEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.42 Does the media prefer GELS or ELYM? In the previous week, Gelteq had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Eliem Therapeutics. Gelteq's average media sentiment score of 1.87 beat Eliem Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media. Company Overall Sentiment Gelteq Very Positive Eliem Therapeutics Neutral Do institutionals & insiders have more ownership in GELS or ELYM? 69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in GELS or ELYM? Eliem Therapeutics received 9 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGelteqN/AN/AEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% SummaryGelteq beats Eliem Therapeutics on 4 of the 7 factors compared between the two stocks. Remove Ads Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.91M$6.91B$5.63B$7.83BDividend YieldN/A2.79%5.33%4.01%P/E RatioN/A7.2623.6118.74Price / SalesN/A218.67384.7890.78Price / CashN/A65.6738.1734.64Price / BookN/A6.386.874.23Net IncomeN/A$142.34M$3.20B$247.47M7 Day Performance0.96%-5.83%-3.57%-3.56%1 Month Performance-35.98%-7.55%1.50%-5.81%1 Year PerformanceN/A-11.06%9.09%-0.96% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.05-3.2%N/AN/A$9.91MN/A0.00N/AELYMEliem TherapeuticsN/A$1.32-5.7%N/A-53.3%$39.27MN/A-2.499DTILPrecision BioSciences4.3005 of 5 stars$5.01+0.6%$37.67+651.8%-65.3%$38.43M$75.10M83.51200Earnings ReportAnalyst ForecastShort Interest ↓High Trading VolumeBLUEbluebird bio2.9637 of 5 stars$3.93-0.3%$51.00+1,197.7%-84.1%$38.21M$53.12M-0.11520Analyst ForecastATNMActinium Pharmaceuticals1.7778 of 5 stars$1.21+1.7%$7.40+511.6%N/A$37.75M$81,000.00-0.8730Analyst RevisionNews CoverageGap UpFBLGFibroBiologics2.1445 of 5 stars$1.02+4.1%$13.00+1,174.5%-91.2%$37.14MN/A0.0010Upcoming EarningsMDCXMedicus PharmaN/A$3.11+1.0%$10.00+221.5%N/A$37.08MN/A0.00N/AEarnings ReportPositive NewsGap UpNRXPNRx Pharmaceuticals2.5952 of 5 stars$2.18-0.9%$31.67+1,352.6%-95.7%$36.88MN/A-1.022SRZNSurrozen3.4188 of 5 stars$11.31+7.7%$38.50+240.5%-29.9%$36.74M$10M0.0080Insider TradeGap UpIRDOpus Genetics2.5219 of 5 stars$1.15+3.6%$8.00+595.7%N/A$36.30M$8.38M-1.0614Upcoming EarningsGBIOGeneration Bio4.2914 of 5 stars$0.54-3.0%$7.33+1,249.5%-89.5%$36.30M$18.58M-0.25150Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Eliem Therapeutics Competitors Precision BioSciences Competitors bluebird bio Competitors Actinium Pharmaceuticals Competitors FibroBiologics Competitors Medicus Pharma Competitors NRx Pharmaceuticals Competitors Surrozen Competitors Opus Genetics Competitors Generation Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
